留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

共载阿霉素和依克立达的PLGA纳米粒的制备及表征

陈大中 高洁 解方园 张翮 鲁莹 邹豪 钟延强

陈大中, 高洁, 解方园, 张翮, 鲁莹, 邹豪, 钟延强. 共载阿霉素和依克立达的PLGA纳米粒的制备及表征[J]. 药学实践与服务, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007
引用本文: 陈大中, 高洁, 解方园, 张翮, 鲁莹, 邹豪, 钟延强. 共载阿霉素和依克立达的PLGA纳米粒的制备及表征[J]. 药学实践与服务, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007
CHEN Dazhong, GAO Jie, XIE Fangyuan, ZHANG He, LU Ying, ZOU Hao, ZHONG Yanqiang. Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007
Citation: CHEN Dazhong, GAO Jie, XIE Fangyuan, ZHANG He, LU Ying, ZOU Hao, ZHONG Yanqiang. Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007

共载阿霉素和依克立达的PLGA纳米粒的制备及表征

doi: 10.3969/j.issn.1006-0111.2017.03.007
基金项目: 国家自然科学基金资助项目(81573376)

Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles

  • 摘要: 目的 建立药物测定方法,并制备共载阿霉素和依克立达的PLGA纳米粒。 方法 利用紫外分光光度法(UV)和高效液相色谱法(HPLC)分别建立阿霉素和依克立达的测定方法;采用纳米沉淀法制备共载纳米粒,通过调节两药的投药比,优化处方,考察纳米粒的粒径、形态、包封率、载药量以及体外释放。 结果 阿霉素在1~40 μg/ml浓度范围内线性关系良好,标准曲线回归方程为A=0.021C+0.002,r=0.999 5; 依克立达在0.5~100 μg/ml浓度范围内线性关系良好,标准曲线回归方程为A=120 742.462 6C+1 974.570 4,r=1.000 0;通过处方优化,共载纳米粒的粒径约为50 nm,分布均一,呈圆形,阿霉素和依克立达的包封率分别为56.58%、51.66%,载药量分别为1.48%、1.85%,两药摩尔比约为1:1;体外释放缓慢。 结论 分别建立了方便快捷、结果准确、重复性好的阿霉素和依克立达的检测方法,并且制备了分散性好、粒径较小的纳米粒,为后续实验提供基础。
  • [1] Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001,414(6859):105-111.
    [2] Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138(4):645-659.
    [3] Cojoc M, Mäbert K, Muders MH, et al. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms[J]. Semin Cancer Biol, 2014, 31:16-27.
    [4] Hubensack M, Müller C, Höcherl P, et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice[J]. J Cancer Res Clin Oncol, 2008, 134(5): 597-607.
    [5] Karla PK, Earla R, Boddu SH, et al. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells[J]. Curr Eye Res, 2009, 34(1): 1-9.
    [6] Nieto Montesinos RM, Beduneau A, Lamprecht A, et al. Liposomes co-loaded with elacridar and tariquidar to modulate the P-glycoprotein at the blood-brain barrier[J]. Mol Pharm, 2015, 12(11):3829-3838.
    [7] Wong HL, Bendayan R, Rauth AM, et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer[J]. J Control Release, 2006, 116(3):275-284.
    [8] Singh MS, Lamprecht A. Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin[J]. Int J Pharm, 2015, 478(2):745-752.
    [9] Planting AST,Sonneveld P,Gaast AVD,et al.A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors[J].Cancer Chemother Pharmacol,2005,55(1):91-99.
    [10] Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery[J]. Biomaterials, 2007, 28(5):869-876.
    [11] Zhu H, Chen H, Zeng X, et al. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance[J]. Biomaterials, 2013, 35(7):2391-2400.
  • [1] 丁千雪, 尚圣兰, 余梦辰, 余爱荣.  机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
    [2] 赖立勇, 夏天爽, 徐圣焱, 蒋益萍, 岳小强, 辛海量.  中药青蒿抗氧化活性的谱效关系研究 . 药学实践与服务, 2024, 42(5): 203-210, 216. doi: 10.12206/j.issn.2097-2024.202211012
  • 加载中
计量
  • 文章访问数:  3040
  • HTML全文浏览量:  363
  • PDF下载量:  1252
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-01-18
  • 修回日期:  2017-03-31

共载阿霉素和依克立达的PLGA纳米粒的制备及表征

doi: 10.3969/j.issn.1006-0111.2017.03.007
    基金项目:  国家自然科学基金资助项目(81573376)

摘要: 目的 建立药物测定方法,并制备共载阿霉素和依克立达的PLGA纳米粒。 方法 利用紫外分光光度法(UV)和高效液相色谱法(HPLC)分别建立阿霉素和依克立达的测定方法;采用纳米沉淀法制备共载纳米粒,通过调节两药的投药比,优化处方,考察纳米粒的粒径、形态、包封率、载药量以及体外释放。 结果 阿霉素在1~40 μg/ml浓度范围内线性关系良好,标准曲线回归方程为A=0.021C+0.002,r=0.999 5; 依克立达在0.5~100 μg/ml浓度范围内线性关系良好,标准曲线回归方程为A=120 742.462 6C+1 974.570 4,r=1.000 0;通过处方优化,共载纳米粒的粒径约为50 nm,分布均一,呈圆形,阿霉素和依克立达的包封率分别为56.58%、51.66%,载药量分别为1.48%、1.85%,两药摩尔比约为1:1;体外释放缓慢。 结论 分别建立了方便快捷、结果准确、重复性好的阿霉素和依克立达的检测方法,并且制备了分散性好、粒径较小的纳米粒,为后续实验提供基础。

English Abstract

陈大中, 高洁, 解方园, 张翮, 鲁莹, 邹豪, 钟延强. 共载阿霉素和依克立达的PLGA纳米粒的制备及表征[J]. 药学实践与服务, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007
引用本文: 陈大中, 高洁, 解方园, 张翮, 鲁莹, 邹豪, 钟延强. 共载阿霉素和依克立达的PLGA纳米粒的制备及表征[J]. 药学实践与服务, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007
CHEN Dazhong, GAO Jie, XIE Fangyuan, ZHANG He, LU Ying, ZOU Hao, ZHONG Yanqiang. Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007
Citation: CHEN Dazhong, GAO Jie, XIE Fangyuan, ZHANG He, LU Ying, ZOU Hao, ZHONG Yanqiang. Preparation and characterization of co-delivery of doxorubicin and elacridar in nanoparticles[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 219-223,251. doi: 10.3969/j.issn.1006-0111.2017.03.007
参考文献 (11)

目录

    /

    返回文章
    返回